EpiVax Therapeutics ("EVT"), founded in 2017, employs a world-leading technology, developed over 22 years by EpiVax, to design vaccines that aim to activate the body’s T cells to cure or prevent disease in the host.

Biotechnology

EpiVax Therapeutics

EpiVax Therapeutics' headquarters in Providence, RI, United States

Annie De Groot

Gregory Covino

Gary Steinberg

William Martin

Manon Cox

Judy Lieberman

Dominique Bridon

Richard Lipkin

Dan Adams

Amy Rosenberg

Eleanor Ramos

The Advisory Team at EpiVax Therapeutics serves as a critical resource for strategic guidance and expert insight on vaccine development and T cell activation technologies. Comprised of experienced professionals, the team collaborates with internal stakeholders to identify innovative approaches, navigate industry challenges, and drive the scientific agenda, ultimately enhancing the company’s mission to create effective therapeutic solutions.

Advisory Team

The Leadership Team at EpiVax Therapeutics is responsible for guiding the company's strategic direction and ensuring successful implementation of its innovative vaccine technologies. Comprising experts in medicine, technology, and operations, the team collaborates to enhance research and development initiatives, oversee regulatory compliance, and drive business growth, all while striving to advance the therapeutic potential of T cell activation for disease prevention and treatment.

EpiVax Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

EpiVax Therapeutics

Org chart

Board & advisors

Teams

Advisory Team

Leadership Team

Offices

Related companies